Solid Biosciences Advances Duchenne Gene Therapy with FDA Meeting on Horizon — Solid Biosciences Inc.

Event summary

SGT-003 dosed in 53 participants in Phase 1/2 INSPIRE DUCHENNE trial as of August 4, 2026.
FDA meeting scheduled for late Q4 2026 to discuss accelerated approval pathway for SGT-003.
Phase 3 IMPACT DUCHENNE trial commenced in Q2 2026 with clinical sites active in Australia and Canada.
SGT-212 for Friedreich’s ataxia dosed in two participants, initial data expected in Q1 2027.
$377.7 million cash position as of June 30, 2026, with runway into mid-2028.

The big picture

Solid Biosciences is positioning itself as a leader in precision genetic medicines for neuromuscular and cardiac diseases. The upcoming FDA meeting on SGT-003 could be a pivotal moment, potentially accelerating the approval process for this Duchenne muscular dystrophy treatment. The company's strong cash position provides a buffer for continued development, but the success of its clinical trials will be critical in maintaining investor confidence.

What we're watching

Regulatory Pathway: Whether the FDA meeting in late Q4 2026 will yield a clear path to accelerated approval for SGT-003.
Clinical Progress: The pace at which Solid Biosciences can enroll participants and generate data for SGT-212 in the FALCON trial.
Financial Runway: How Solid Biosciences will manage its cash position to support late-stage development and early pipeline opportunities into mid-2028.